CardioComm Receives TSX Venture Exchange Approval for Announced Loan Facility
CardioComm (TSXV:EKG / OTC:EKGGF) received TSX Venture Exchange approval for a $512,000 loan facility dated November 3, 2025 to fund completion and commercialization of its GEMS FLEX and 14-day Holter/LTCM ECG platform (the Flagship Product).
The financing includes issuance of 345,600 common shares and 6,912,000 warrants to lenders (related parties), with each warrant exercisable at $0.05 until November 3, 2030 and a four-month hold ending March 11, 2026. The company said funds will finalize product, run user feedback reviews, launch targeted marketing, and provide post-launch support.
CardioComm (TSXV:EKG / OTC:EKGGF) ha ottenuto l'approvazione dello TSX Venture Exchange per una linea di prestito di 512.000 dollari datata 3 novembre 2025 per finanziare il completamento e la commercializzazione della sua piattaforma GEMS FLEX e Holter/LTCM ECG di 14 giorni (il prodotto di punta).
Il finanziamento prevede l'emissione di 345.600 azioni ordinarie e 6.912.000 warrant agli istituti finanziatori (parti correlate), con ogni warrant esercitabile a 0,05 dollari fino al 3 novembre 2030 e un periodo di lock-up di quattro mesi che termina l'11 marzo 2026. L'azienda ha dichiarato che i fondi serviranno a finalizzare il prodotto, a raccogliere feedback dagli utenti, a lanciare campagne di marketing mirate e a fornire supporto post-lancio.
CardioComm (TSXV:EKG / OTC:EKGGF) recibió la aprobación de la TSX Venture Exchange para una línea de préstamo de 512.000 dólares con fecha del 3 de noviembre de 2025 para financiar la finalización y comercialización de su plataforma GEMS FLEX y Holter/LTCM ECG de 14 días (el producto insignia).
El financiamiento incluye la emisión de 345.600 acciones comunes y 6.912.000 warrants a los prestamistas (partes relacionadas), con cada warrant ejercitable a 0,05 dólares hasta el 3 de noviembre de 2030 y un periodo de bloqueo de cuatro meses que finaliza el 11 de marzo de 2026. La compañía indicó que los fondos permitirán finalizar el producto, realizar revisiones de retroalimentación de usuarios, lanzar marketing dirigido y brindar soporte post-lanzamiento.
CardioComm (TSXV:EKG / OTC:EKGGF) 는 2025년 11월 3일자로 작성된 512,000달러의 대출 시설에 대해 TSX Venture Exchange의 승인을 받았으며, 이를 통해 자사 주력 제품인 GEMS FLEX 및 14일 Holter/LTCM ECG 플랫폼의 완성과 상용화를 자금 조달합니다.
파이낸싱에는 대출자(관련 당사자)에게 345,600주 보통주 및 6,912,000주의 워런트를 발행하는 것이 포함되며, 각 워런트는 0.05달러의 행사 가격으로 2030년 11월 3일까지 행사 가능하고 4개월의 보유 기간은 2026년 3월 11일에 만료됩니다. 회사는 자금으로 제품을 최종화하고, 사용자 피드백 검토를 실시하며, 표적 마케팅을 시작하고, 출시 후 지원을 제공할 것이라고 밝혔습니다.
CardioComm (TSXV:EKG / OTC:EKGGF) a reçu l'approbation de la TSX Venture Exchange pour une ligne de prêt de 512 000 $ datée du 3 novembre 2025 afin de financer l'achèvement et la commercialisation de sa plateforme GEMS FLEX et Holter/LTCM ECG de 14 jours (le produit phare).
Le financement prévoit l'émission de 345 600 actions ordinaires et 6 912 000 warrants aux prêteurs (parties liées), chaque warrant étant exerçable à 0,05 $ jusqu'au 3 novembre 2030 et une période de blocage de quatre mois se terminant le 11 mars 2026. L'entreprise a déclaré que les fonds permettront de finaliser le produit, de réaliser des revues de retours utilisateurs, de lancer un marketing ciblé et de fournir un soutien post-lancement.
CardioComm (TSXV:EKG / OTC:EKGGF) erhielt die Genehmigung der TSX Venture Exchange für eine Kreditfazilität in Höhe von 512.000 $ datiert auf den 3. November 2025, um die Fertigstellung und Vermarktung der Plattform GEMS FLEX und 14-tägige Holter/LTCM-ECG-Plattform (das Flaggschiffprodukt) zu finanzieren.
Die Finanzierung beinhaltet die Ausgabe von 345.600 Stammaktien und 6.912.000 Warrants an Kreditgeber (relevante Parteien), wobei jeder Warrant bis zum 3. November 2030 zu einem Ausübungspreis von 0,05 $ ausgeübt werden kann und eine Viermonats-Sperrfrist bis zum 11. März 2026 besteht. Das Unternehmen erklärte, dass die Mittel das Produkt finalisieren, Nutzerfeedback prüfen, gezieltes Marketing starten und Nachsorge unterstützen werden.
CardioComm (TSXV:EKG / OTC:EKGGF) تلقت موافقة بورصة TSX Venture Exchange على تسهيل قرض بقيمة 512.000 دولار بتاريخ 3 نوفمبر 2025 لتمويل إكمال وتسويق منصتها GEMS FLEX وHolter/LTCM ECG لمدة 14 يوماً (المنتج الرائد).
يشمل التمويل إصدار 345.600 سهم عادي و 6.912.000 وارنِت للمقرضين (أطراف ذات صلة)، حيث يمكن ممارسة كل وارنِت بسعر 0.05 دولار حتى 3 نوفمبر 2030 ووجود قيد حظر لمدة أربعة أشهر ينتهي في 11 مارس 2026. قالت الشركة إن الأموال ستُكمل تطوير المنتج، وتُجري مراجعات ملاحظات المستخدمين، وتطلق تسويقاً موجهًا، وتقدم دعم ما بعد الإطلاق.
- $512,000 loan to fund commercialization
- Funding earmarked to finalize Flagship Product release
- Capital supports user feedback, launch, and post-launch support
- Issued 345,600 common shares and 6,912,000 warrants to lenders
- Majority of Bonus securities issued to related parties (insiders)
- Warrants exercisable at $0.05 until Nov 3, 2030 (potential future dilution)
Funding will be used to a advance GEMS Flex And 14-Day Holter/LTCM ECG Platform
Toronto, Ontario--(Newsfile Corp. - November 10, 2025) - CardioComm Solutions, Inc. (TSXV: EKG) ("CardioComm" or the "Company"), a global medical provider of consumer heart monitoring and medical electrocardiogram ("ECG") software solutions, is pleased to announce that it has received approval from the TSX Venture Exchange for its November 3, 2025 announced loan agreement dated November 3, 2025 (the "Loan Agreement") representing aggregate funding of
The Loan Agreement provides new working capital to complete and commercialize the Company's GEMS FLEX and 14-day Holter and Event long term continuous monitoring ("LTCM") ECG software platform (the "Flagship Product"). The Flagship Product is expected to become CardioComm's principal offering and major source of revenue, providing healthcare professionals and patients with new and advanced remote monitoring and ECG analysis capabilities. This financing transaction will enable the Company to:
- Finalize the Flagship Product for a full market-ready release;
- Conduct structured user feedback reviews to refine usability and performance;
- Launch and market the Flagship Product to targeted healthcare markets; and
- Provide post-launch customer support and installation services.
Pursuant to the Loan Agreement, the Company has issued an aggregate of 345,600 common shares of the Company (each, a "Bonus Share") and 6,912,000 common share purchase warrants of the Company (each, a "Bonus Warrant") to certain of the lenders under the Loan Agreement, as follows: 280,000 Bonus Shares and 5,600,000 Bonus Warrants to Xemxija Holdings Inc. ("Xemxija", a company controlled by Daniel Grima, a director of CardioComm); and 65,600 Bonus Shares and 1,312,000 Bonus Warrants to ITF Ventures Inc. ("ITF", a company controlled by Daniel Grima and Etienne Grima, CEO and a director of CardioComm). Each Bonus Warrant is exercisable to acquire one Company common share at an exercise price of
Related Party Transaction and MI 61-101 Compliance
As the lenders under the Loan Agreement (Xemxija, ITF and Etienne Grima, each a "Lender" and collectively the "Lenders") are insiders of the Company, the loans under the Loan Agreement (the "Loan Transaction") and the issuance of Bonus Shares and Bonus Warrants to Xemxija and ITF (the "Bonus Transaction") are "related party transactions" under Multilateral Instrument 61-101 - Protection of Minority Security Holders in Special Transactions ("MI 61-101"). Each of the Loan Transaction and the Bonus Transaction is exempt from the formal valuation requirement because the Company's securities are not listed on any of the markets specified in section 5.5(b) of MI 61-101. The Loan Transaction is exempt from the minority shareholder approval requirement pursuant to section 5.7(1)(f) of MI 61-101, on the basis that the Loan Transaction contemplates loans being obtained by the Company from related parties on reasonable commercial terms that are not less advantageous to the Company than if the loans were obtained from a person dealing at arm's length with the Company, and the loans are not convertible into or repayable in equity or voting securities of the Company. The Bonus Transaction is exempt from the minority shareholder approval requirement pursuant to section 5.7(1)(a) of MI 61-101 because neither the fair market value of the subject matter of, nor the fair market value of the consideration for, the Bonus Transaction exceeds 25 per cent of the Company's market capitalization. In considering and unanimously approving the Loan Transaction and the Bonus Transaction, there were no materially contrary views, abstentions (except for any abstentions required by corporate law) or material disagreements by any director of the Company. The Company did not file a material change report at least 21 days before executing the Loan Agreement, which was reasonable given the MI 61-101 exemptions noted above and because the Loan Agreement was subject to receipt of TSX Venture Exchange approval.
To learn more about CardioComm's products and for further updates please visit the Company's websites at www.cardiocommsolutions.com and www.theheartcheck.com.
About CardioComm Solutions
CardioComm Solutions' patented and proprietary technology is used in products for recording, viewing, analyzing and storing electrocardiograms for diagnosis and management of cardiac patients. Products are sold worldwide through a combination of an external distribution network and a North American-based sales team. CardioComm Solutions has earned the ISO 13485 and ISO 27001 certifications, is HIPAA compliant and holds medical device clearances and sales licenses from the USA (FDA) and Canada (Health Canada).
FOR FURTHER INFORMATION PLEASE CONTACT:
Etienne Grima, Chief Executive Officer
1-877-977-9425 x227
investor.relations@cardiocommsolutions.com
Forward-looking statements
This release may contain certain forward-looking statements and forward-looking information with respect to the financial condition, results of operations and business of CardioComm Solutions and certain of the plans and objectives of CardioComm Solutions with respect to these items. Such statements and information reflect management's current beliefs and are based on information currently available to management. By their nature, forward-looking statements and forward-looking information involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements and forward-looking information.
In evaluating these statements, readers should not place undue reliance on forward-looking statements and forward-looking information. The Company does not assume any obligation to update the forward-looking statements and forward-looking information contained in this release other than as required by applicable laws, including without limitation, Section 5.8(2) of National Instrument 51-102 (Continuous Disclosure Obligations).
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/273966
FAQ
How much funding did CardioComm (EKGGF) receive under the November 3, 2025 loan agreement?
What will CardioComm use the $512,000 loan for and when will the Flagship Product be commercialized?
What securities did CardioComm issue to lenders and what are the warrant terms?
Are the loans and bonus securities related-party transactions for CardioComm (EKGGF)?
When do the issued Bonus Shares, Bonus Warrants, and shares issuable under warrants become tradable?
